Conceivable Life Sciences operates the world's first fully automated IVF lab, utilizing AI-powered automation to perform over 200 steps in embryo creation. This technology addresses the limited access to IVF by scaling production, improving success rates, and reducing costs, enabling more individuals to benefit from fertility treatments.
Funding
$38M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVFounders
Product
Problem
Traditional in-vitro fertilization (IVF) labs face challenges in scaling production, achieving consistent results, and reducing costs, which limits access to fertility treatments for many individuals. The manual nature of the more than 200 steps required to create an embryo contributes to these limitations.
Solution
Conceivable Life Sciences operates a fully automated IVF lab that leverages AI-powered automation to streamline and standardize the embryo creation process. This end-to-end automation enables increased scale, improved success rates, and reduced costs compared to traditional IVF methods. By automating the critical lab processes, Conceivable aims to make IVF more accessible to a larger population of infertile individuals.
Target Audience
The primary target audience includes individuals and couples experiencing infertility who are seeking more accessible and affordable IVF treatment options, as well as clinicians seeking to expand IVF access to all who need it.
Features
- AI-powered automation of over 200 steps in the embryo creation process
- End-to-end automation for increased scale and efficiency
- Standardized processes for consistent and improved results